Log In
Print
BCIQ
Print
Print this Print this
 

Engauge-cancer-DLBCL

  Manage Alerts
Collapse Summary General Information
Company Aegis Sciences Corp.
DescriptionGene expression assay that combines LMO2 and CD137 (TNFRSF9) gene expression levels with the International Prognostic Index (IPI)
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics: Other diagnostic technologies
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDiagnose and stratify patients with diffuse large B cell lymphoma (DLBCL)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today